.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Covington
Accenture
Fish and Richardson
Moodys
McKesson
Fuji
Mallinckrodt
Healthtrust
Novartis

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,151,444

« Back to Dashboard

Summary for Patent: 5,151,444

Title: Ocular hypotensive agents
Abstract:The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagandins, which shows no transient ocular hypertensive response that PGs usually show.
Inventor(s): Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuji (Nishinomiya, JP), Oda;; Tomio (Itami, JP)
Assignee: K.K. Ueno Seiyaku Oyo Kenkyujo (Osaka, JP)
Application Number:07/584,669
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Dosage form;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,151,444

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan62-235890Sep 18, 1987
Japan62-334037Dec 29, 1987

International Patent Family for Patent: 5,151,444

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0580268► Subscribe
European Patent Office0455264► Subscribe
European Patent Office0366279► Subscribe
European Patent Office0308159► Subscribe
European Patent Office0308135► Subscribe
European Patent Office0289349► Subscribe300135Netherlands► Subscribe
European Patent Office0289349► SubscribeSPC/GB04/007United Kingdom► Subscribe
European Patent Office0289349► SubscribeC300135Netherlands► Subscribe
Germany3868127► Subscribe
Germany3876050► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Colorcon
Chubb
Julphar
UBS
Merck
Citi
Chinese Patent Office
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot